Multiple myeloma cell line U266 apoptosis induced by velcade.
- Author:
Li-Juan CHEN
1
;
Jian-Yong LI
;
Si-Xuan QIAN
;
Guang-Rong ZHU
;
Wen-Juan ZHENG
Author Information
1. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province People Hospital, Nanjing 210029, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
pharmacology;
Apoptosis;
drug effects;
Boronic Acids;
pharmacology;
Bortezomib;
Cell Line, Tumor;
Cell Proliferation;
drug effects;
Humans;
Multiple Myeloma;
metabolism;
pathology;
Proto-Oncogene Proteins c-bcl-2;
biosynthesis;
genetics;
Pyrazines;
pharmacology;
RNA, Messenger;
biosynthesis;
genetics
- From:
Journal of Experimental Hematology
2006;14(4):696-699
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the effect of velcade on multiple myeloma cell line U266 apoptosis and its mechanism, cell viability was estimated by trypan blue dye exclusion. Annexin-V, mitochondrial transmembrane potential (delta psi m) and reactive oxygen species (ROS) labeled by DCFHDA were examined by flow cytometry, the expression of bcl-2 mRNA was detected by semi-quantitative RT-PCR. The results showed that the velcade inhibited the growth of U266 cells and reduced cell viability accompanied by appearance of morphologic characteristics of apoptosis. Velcade at 50 nmol/L increased Annexin V positivity and fluorescence intensity of DCF because of ROS generation while it decreased the delta psi m of U266 cells. Expression of anti-apoptotic gene bcl-2 mRNA also decreased. It is concluded that velcade inhibited the growth and reduce cell viability of U266 cells. Velcade can induce U266 cells apoptosis by intrinsic cell apoptotic pathway.
